In addition, the investigators said, the early and continuous separation of treatment curves suggested that "rEEG’s superiority in reducing patients’ depressive symptoms might have continued had the trial continued."
The study was sponsored by CNS Response Inc., the company that owns the rEEG platform. Dr. DeBattista said he has received research support from the company, as have 4 of the other 14 investigators. Four other investigators are company employees and own stock in CNS Response.